JP2021504370A5 - - Google Patents

Download PDF

Info

Publication number
JP2021504370A5
JP2021504370A5 JP2020528867A JP2020528867A JP2021504370A5 JP 2021504370 A5 JP2021504370 A5 JP 2021504370A5 JP 2020528867 A JP2020528867 A JP 2020528867A JP 2020528867 A JP2020528867 A JP 2020528867A JP 2021504370 A5 JP2021504370 A5 JP 2021504370A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
dose
unit dosage
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020528867A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021504370A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/059383 external-priority patent/WO2019106550A1/en
Publication of JP2021504370A publication Critical patent/JP2021504370A/ja
Publication of JP2021504370A5 publication Critical patent/JP2021504370A5/ja
Pending legal-status Critical Current

Links

JP2020528867A 2017-11-30 2018-11-28 肝疾患を治療するためのfxr作動薬 Pending JP2021504370A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762593084P 2017-11-30 2017-11-30
US62/593,084 2017-11-30
PCT/IB2018/059383 WO2019106550A1 (en) 2017-11-30 2018-11-28 Fxr agonists for the treatment of liver diseases

Publications (2)

Publication Number Publication Date
JP2021504370A JP2021504370A (ja) 2021-02-15
JP2021504370A5 true JP2021504370A5 (cg-RX-API-DMAC7.html) 2022-01-06

Family

ID=64959384

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020528867A Pending JP2021504370A (ja) 2017-11-30 2018-11-28 肝疾患を治療するためのfxr作動薬

Country Status (12)

Country Link
US (2) US20210361638A1 (cg-RX-API-DMAC7.html)
EP (1) EP3716977A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021504370A (cg-RX-API-DMAC7.html)
KR (1) KR20200094175A (cg-RX-API-DMAC7.html)
CN (1) CN111356458A (cg-RX-API-DMAC7.html)
AU (1) AU2018376904B2 (cg-RX-API-DMAC7.html)
CA (1) CA3081656A1 (cg-RX-API-DMAC7.html)
IL (1) IL274747A (cg-RX-API-DMAC7.html)
MX (1) MX2020005557A (cg-RX-API-DMAC7.html)
RU (1) RU2020121222A (cg-RX-API-DMAC7.html)
TW (1) TW201936189A (cg-RX-API-DMAC7.html)
WO (1) WO2019106550A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021014349A1 (en) * 2019-07-23 2021-01-28 Novartis Ag Treatment comprising fxr agonists
CN114502198A (zh) * 2019-09-30 2022-05-13 诺华股份有限公司 包括使用fxr激动剂的治疗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089316A2 (en) * 2004-03-12 2005-09-29 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
LT3419625T (lt) 2016-02-22 2021-07-26 Novartis Ag Fxr agonistų panaudojimo būdai
HK1257648A1 (zh) * 2016-02-22 2019-10-25 Novartis Ag Fxr促效剂之使用方法
SI3419624T1 (sl) * 2016-02-22 2021-05-31 Novartis Ag Postopki za uporabo agonistov FXR
AR114930A1 (es) * 2017-09-12 2020-11-11 Novartis Ag Composición farmacéutica

Similar Documents

Publication Publication Date Title
RU2018133298A (ru) Способы применения агонистов fxr
JP2018507914A5 (cg-RX-API-DMAC7.html)
JP6762931B2 (ja) 経鼻組成物と該経鼻組成物の使用方法の改善
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP6099609B2 (ja) 肺炎症を低減するためのレボフロキサシンの吸入
HRP20230272T1 (hr) Postupci za liječenje cistične fibroze
HRP20231142T3 (hr) Kontrolirano oslobađanje 25-hidroksivitamina d
ES2701094T3 (es) Tratamiento de enfermedades colestáticas intrahepáticas
JP2020503269A5 (cg-RX-API-DMAC7.html)
TW201733583A (zh) Fxr促效劑之使用方法
JP2010518122A5 (cg-RX-API-DMAC7.html)
CN102655859A (zh) 病毒感染的组合疗法治疗
JP2020504129A (ja) 非アルコール性脂肪性肝炎(nash)および肝線維症のための併用療法
JP2020533296A5 (cg-RX-API-DMAC7.html)
JP2020500864A5 (cg-RX-API-DMAC7.html)
JP2021509395A5 (cg-RX-API-DMAC7.html)
JP2014521641A5 (cg-RX-API-DMAC7.html)
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
HRP20251043T1 (hr) Novi oralni farmaceutski pripravak i režim doziranja za terapiju progresivnih fibrozirajućih intersticijskih bolesti pluća
HUE025567T2 (en) Agents containing vasoconstrictors for combination therapy
CA3163375A1 (en) Treatment of primary biliary cholangitis with elafibranor
JP2016505050A5 (cg-RX-API-DMAC7.html)
RU2017127509A (ru) Композиции и способы для улучшенного мышечного метаболизма
JP2019507786A5 (cg-RX-API-DMAC7.html)
JP2020519576A5 (cg-RX-API-DMAC7.html)